drug

Dexmedetomidine

MeSH D020927
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Washington University School of Medicine
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
NCT06093451Phase 4Unknown
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
NCT00205712Phase 4Completed

KOLs & investigators

1
John W. Newcomer, M.D.KOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Washington University School of Medicine
company
trial
Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
PHASE4
trial
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
PHASE4
trial
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Psychoses, Substance-Induced
indication
Schizophrenia Agitation
indication
KOL
John W. Newcomer, M.D.
KOL score 5
person